polygenic risk score/polygenic score

An analysis of genomic data from nearly 250,000 participants in the National Institutes of Health’s All of Us Research Program has identified more than 275 million previously unreported genetic variations, nearly 4 million of which have potential health consequences.

Accounting for genetic variability in biomarkers not associated with cancer risk could avoid unnecessary diagnostic procedures, Vanderbilt researchers found.

Polygenic risk scores — scores that reflect the influence of common genetic variants — could be used to predict the likelihood of developing chronic overlapping pain conditions and guide biomarker and targeted prevention efforts.

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

Report finds polygenic embryo screening (PES) does not provide an accurate measure of the risk of developing psychiatric disorders later in life.

Vanderbilt University Medical Center has received a five-year, $4.5 million grant from the National Human Genome Research Institute to assess clinical outcomes and economic value of screening large, diverse health care populations for disease risk using polygenic risk scores.

Vanderbilt researchers have discovered that a genetic predisposition to elevated body mass index increases the risk of diastolic dysfunction — a cardiac condition that can lead to heart failure.